Q. Let"s turn to testing, specifically rapid antigen testing. The U.S. has been a little bit slower to adopt this than some other countries. Most recently, the Biden administration announced that people with private insurance will be able to get reimbursement for rapid antigen testing. Are we doing all we can to provide access to this type of testing?
A. The advent of at-home rapid test is probably the biggest paradigm change in regulation of medical products to come out of the pandemic. If you would have said to me when I was at FDA that we will authorize tests to allow people to test at home for infectious diseases, I would have told you it"s never going to happen. And you saw all the resistance of the agency going back a couple decades, and I was there during this time, of allowing at-home HIV tests. There was a view that if you allowed someone to self-diagnose for something that was a serious illness, there was no guarantee that they"re going to take appropriate actions on the basis of that test result. And with COVID they just got over it. This is going to open up a whole new field of at-home testing for a range of pathogens. We really kind of have a critical window here. We still have three, four, hard months ahead. We have the back end of the delta wave, and then we have omicron to deal with. Flooding the market with home diagnostic tests for the next four months to me makes eminent sense, and the best way to do that is to directly subsidize it. If you get enough tests out there, people aren"t going to hoard them, because they"re going to recognize they"re just widely available. You go to the U.K., they offer you tests in pharmacy now people turn them down – like I have enough already.